A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Standard therapies used for the treatment of acute myeloid leukemia (AML) are cytotoxic agents that target rapidly proliferating cells. Unfortunately, this therapeutic approach has limited efficacy and significant toxicity and the majority of AML patients still die of their disease. In contrast to the poor prognosis of most AML patients, most individuals with a rare subtype of AML, acute promyelocytic leukemia, can be cured by differentiation therapy using regimens containing all-trans retinoic acid. GSK3 has been previously identified as a therapeutic target in AML where its inhibition can lead to the differentiation and growth arrest of leukemic cells. Unfortunately, existing GSK3 inhibitors lead to suboptimal differentiation activity making them less useful as clinical AML differentiation agents. Here, we describe the discovery of a novel GSK3 inhibitor, GS87. GS87 was discovered in efforts to optimize GSK3 inhibition for AML differentiation activity. Despite GS87's dramatic ability to induce AML differentiation, kinase profiling reveals its high specificity in targeting GSK3 as compared with other kinases. GS87 demonstrates high efficacy in a mouse AML model system and unlike current AML therapeutics, exhibits little effect on normal bone marrow cells. GS87 induces potent differentiation by more effectively activating GSK3-dependent signaling components including MAPK signaling as compared with other GSK3 inhibitors. GS87 is a novel GSK3 inhibitor with therapeutic potential as a differentiation agent for non-promyelocytic AML. Mol Cancer Ther; 15(7); 1485–94. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611 · cited 1×
“Differentiation therapy has demonstrated remarkable clinical efficacy for a small subset of AML patients with APL reinforcing its potential as an attractive therapeutic strategy for this disease (2).”
BackgroundLithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321
Scott, L., Civin, C., Rorth, P., & Friedman, A. (1992) · Blood · doi:10.1182/blood.v80.7.1725.1725 · Cited by 409
Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study
del Ser, T., Steinwachs, K. C., Gertz, H. J., Andrés, M. V., Gómez-Carrillo, B., Medina, M., Vericat, J. A., Redondo, P., Fleet, D., & León, T. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120805 · Cited by 329 · cited 1×
“LY2090314 and tideglusib are more specific small-molecule GSK3 inhibitors utilized in humans in clinical trials (16, 17).”
BackgroundA phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy
Tolosa, E., Litvan, I., Höglinger, G. U., Burn, D., Lees, A., Andrés, M. V., Gómez‐Carrillo, B., León, T., del Ser, T., & for the TAUROS Investigators (2014) · Movement Disorders · doi:10.1002/mds.25824 · Cited by 320
Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy
Wang, Z., Smith, K. S., Murphy, M., Piloto, O., Somervaille, T. C. P., & Cleary, M. L. (2008) · Nature · doi:10.1038/nature07284 · Cited by 265
Banerji, V., Frumm, S. M., Ross, K. N., Li, L. S., Schinzel, A. C., Hahn, C. K., Kakoza, R. M., Chow, K. T., Ross, L., Alexe, G., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci46465 · Cited by 105
Holmes, T., O'Brien, T. A., Knight, R., Lindeman, R., Shen, S., Song, E., Symonds, G., & Dolnikov, A. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0600 · Cited by 68
GSK3β inactivation induces apoptosis of leukemia cells by repressing the function of c-Myb
Zhou, F., Zhang, L., van Laar, T., van Dam, H., & ten Dijke, P. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-06-0483 · Cited by 55
Cited by
Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
Duda, P., Akula, S. M., Abrams, S. L., Steelman, L. S., Martelli, A. M., Cocco, L., Ratti, S., Candido, S., Libra, M., Montalto, G., et al. (2020) · Cells · doi:10.3390/cells9051110 · Cited by 284
“GS87 had little effects on normal bone marrow cells [44].”
BackgroundGSK-3 as a novel prognostic indicator in leukemia
Ruvolo, P. P. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.05.001 · Cited by 39
“It was not clear in that study if GSK3 activation was required or necessary for RGS2 mediated differentiation of the various AML cells but GSK3 is well established as a regulator of myeloid differentiation (Gupta et al., 2012; Banerji et al., 2012; Lochab et al., 2013; Hu et al., 2016).”
BackgroundMishra, M., Thacker, G., Sharma, A., Singh, A. K., Upadhyay, V., Sanyal, S., Verma, S. P., Tripathi, A. K., Bhatt, M. L. B., & Trivedi, A. K. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0268 · Cited by 30
GSK3α: An Important Paralog in Neurodegenerative Disorders and Cancer
Silva-García, O., Cortés-Vieyra, R., Mendoza-Ambrosio, F. N., Ramírez-Galicia, G., & Baizabal-Aguirre, V. M. (2020) · Biomolecules · doi:10.3390/biom10121683 · Cited by 17
Metadata
- Authors
- Hu, S., Ueda, M., Stetson, L., Ignatz-Hoover, J., Moreton, S., Chakrabarti, A., Xia, Z., Karan, G., de Lima, M., Agrawal, M. K., & Wald, D. N.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2016-07-01
- Volume
- 15
- Issue
- 7
- Pages
- 1485-1494
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2388625588
- Cited by
- 38
- References
- 12
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity. https://app.cochat.ai/papers/10.1158/1535-7163.mct-15-0566
- The paper
- Hu, S., Ueda, M., Stetson, L., Ignatz-Hoover, J., Moreton, S., Chakrabarti, A., Xia, Z., Karan, G., de Lima, M., Agrawal, M. K., & Wald, D. N. (2016). A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-15-0566
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.